Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The International Tirazone Triple Trial (i3T): A Phase III, Randomized Efficacy And Safety Study Of The Combination Chemotherapy With Tirapazamine+Cisplatin+Vinorelbine Versus Cisplatin+Vinorelbine In Subjects With Inoperable, Previously Untreated, Non-Small Cell Lung Cancer

NCT00017459 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00017459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00017459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The International Tirazone Triple Trial (i3T): A Phase III, Randomized Efficacy And Safety Study Of The Combination Chemotherapy With Tirapazamine+Cisplatin+Vinorelbine Versus Cisplatin+Vinorelbine In Subjects With Inoperable, Previously Untreated, Non-Small Cell Lung Cancer
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2000
Completion date
February 29, 2004
Enrollment
Not reported
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer